Myles Brown (Dana-Farber Cancer Institute, Boston, US)

Essential genes and cistromes regulating breast cancer hormone dependence

Luca Magnani (Imperial College, London, UK)

Diving into the dark matter of the breast cancer genome

Joyce M Slingerland (University of Miami Miller School of Medicine, Miami, US)

Estrone cooperates with the NFkB pathway to promote obesity-driven inflammation and postmenopausal ER+ breast cancer progression

Senthil Muthuswamy (Beth Israel Deaconess Medical Center, Boston, US)

Cell polarity proteins, patient derived organoids and endocrine resistance

Carol Sartorius (University of Colorado, Aurora, US)

Progestin action in luminal and luminobasal models of breast cancer

Cathrin Brisken (Ecole Polytechnique Fédérale, Lausanne, CH)

Humanizing the mouse mammary gland to study hormone-dependent breast carcinogenesis

Christopher Lord (The Institute of Cancer Research, London, UK)

René Bernards (Netherlands Cancer Institute, Amsterdam, NL)

Exploiting senescence for cancer therapy

William J. Muller (Rosalind and Morris Goodman Cancer Center, Montreal, CA)

Evaluating the role of Integrin signaling in breast cancer dormancy

Carlos Caldas (Cancer Research UK Cambridge Institute, Cambridge, UK)

Know thy enemy: Landscapes of lethal breast cancer

Steffi Oesterreich (University of Pittsburgh, Pittsburgh, US)

Estrogen receptor mutations

Mohamed Bentires-Alj (University of Basel, Basel, CH)

Cancer targeted therapy and tumor heterogeneity: Act locally, think globally

Karin E. de Visser (Netherlands Cancer Institute, Amsterdam, NL)

The genetic makeup of primary breast cancer dictates pro-metastatic systemic inflammation

Jean Zhao (Dana-Farber Cancer Institute, Boston, US)

Integrating immunotherapy and targeted therapies in cancer treatment: from mouse models to human therapies

Kornelia Polyak (Dana-Farber Cancer Institute, Boston, US)

Immunotherapies and immunoprevention in breast cancer

Morag Park (Rosalind and Morris Goodman Cancer Center, Montreal, CA)

Functional heterogeneity of the triple-negative breast cancer microenvironment

Alexandra Van Keymeulen (Université Libre de Bruxelles, Bruxelles, BE)

Multipotency and lineage segregation of mammary stem cells

Silvia Fre (Institut Curie, Paris, FR)

New approaches to study mammary cell fate specification during embryonic morphogenesis

Jacco van Rheenen (Netherlands Cancer Institute, Amsterdam, NL)

Dissection of the cellular composition of breast tumors for optimal treatment selection

Walid T. Khaled (University of Cambridge, Cambridge, UK)

Building a Comprehensive Human Breast Cell Atlas and studying early stages of TNBC by using scRNAseq

Kienan I. Savage (Queen’s University Belfast, Belfast, UK)

Topoisomerase II inhibitors enhance STING-dependent cytokine release and immune checkpoint activation

Robert Clarke (University of Manchester, Manchester, UK)

Regulation of breast cancer stem cell activity by the bone metastatic niche

Matthew J. Ellis (Baylor College of Medicine, Houston, US)

Endocrine Therapy Resistance: new insights

Judy E. Garber (Dana-Farber Cancer Institute, Boston, US)

Geoffrey Lindeman (Walter and Eliza Hall Institute of Medical Research, Parkville, AU)

Targeting cell survival pathways in breast cancer using BH3 mimetics

Gastón Soria (Universidad Nacional de Córdoba, Córdoba, AR)

Polo-like Kinase 1 inhibition as a novel therapeutic approach to target BRCA1-deficient cancer cells by synthetic lethality induction

Jennifer K. Richer (University of Colorado, Aurora, US)

Clinical biopsies and preclinical models reveal new therapeutic targets in estrogen receptor mutant metastatic breast cancer

Douglas Perkins (The Institute of Cancer Research, London, UK)

A role for senescent fibroblasts in breast cancer metastasis

Chair: John Hilkens (The Netherlands Cancer Institute, Amsterdam, NL)

Lgr5 Stem Cell-based organoids in human disease